ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment

Oct 16, 2018

Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.

read article

CPH has a Thirst for Bringing its Branded Cannabis Lifestyle Products to the World

Sep 05, 2018

Creso Pharma (ASX:CPH) is one step closer to launching its range of cannabis infused products.

read article

IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops

Jul 17, 2018

Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® product.

read article

MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence

Jul 13, 2018

Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.

read article

Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism

Jul 10, 2018

Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.

read article

Revolutionary MedTech Device: a New Frontier in Autism Treatment

Jun 26, 2018

Today’s company has created the first and only regulated medical device for the management of autism in a home setting.

read article

IMC Reports Rising Revenues & Eyes Colitis Market

Jun 07, 2018

Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

read article

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

May 21, 2018

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.

read article

PTX Breast Cancer Trial Results Exceed Industry Expectations

May 17, 2018

Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.

read article

CPH Continues to Expand Global Footprint As it Moves Into Israeli Cannabis Market

May 16, 2018

Creso Pharma (ASX:CPH) has today informed the market that it has entered into a joint venture with Cohen Propagation Nurseries Limited to operate a high quality medicinal cannabis growing facility in Israel.

read article

MXC to Build Malta Production Facility to Capitalise on $55B Global Pot Market

Apr 12, 2018

MGC Pharmaceuticals (ASX:MXC) has wasted no time ramping up its game in 2018.

read article

ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

Mar 13, 2018

This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.

read article

Blockbuster Results from IMC’s NASH Liver Therapy Trials

Mar 08, 2018

Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC | NASDAQ:IMRN) continues to progress its oral immunotherapies, to supply solutions for a growing unmet need.

read article

RSH on verge of commercialisation: on track to complete next-generation AirSonea

Feb 23, 2018

Respiri (ASX:RSH) is leading the way in new technologies to better manage asthma, a chronic disease affecting more than 330 million worldwide.

read article

CPH Gets Green Light to Distribute its Innovative CBD Based Nutraceutical Products in the UK

Jan 18, 2018

While much of the business world shut down over the Christmas-New Year’s break, diversified cannabis healthcare company Creso Pharma (ASX:CPH) has been busy on a number of fronts.

read article

CPH Seal Swiss Pharma Deal: Setting the Cornerstone for Global Commercialisation of cannaQIX

Dec 04, 2017

It has been a major month for Creso Pharma (ASX:CPH) as it continues to make potentially market moving announcements.

read article

Budding ASX Junior Pens Transformative Medical Cannabis Deals: Now Generating Revenue

Nov 23, 2017

MGC Pharmaceuticals (ASX:MXC) was the second company to originally emerge in the ASX cannabis corridor, and with a whip-smart team that’s put in serious hours in the industry-leading Israeli medicinal marijuana scene, this ASX junior is rapidly coming into its own.

read article

Could One ASX Junior Have All the Elements to Crack $121BN Natural Skincare Market?

Nov 15, 2017

This Australian-based developer of US FDA and Australia TGA approved natural and organic skin care products already has mainstream reach spanning over 15 countries, through its 100% natural and organic sunscreen Soleo Organics and is set to launch its organics sunscreen range into the US$10BN global suncare market.

read article
Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.